Third, the same concept may apply to CSF t-tau and p-tau, which are often used to stage preclinical AD and are viewed as biomarkers of a “disease state,” despite potentially correlating with OI ability (Mattsson et al., 2017; Lian et al., 2019). The gene discussed is MAPT; the disease is Alzheimer disease.